Vanguard Global Advisers
CGTX icon

Vanguard Global Advisers’s Cognition Therapeutics CGTX Stock Holding History

Vanguard Global Advisers’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.2K Hold
23,641
– – ﹤0.01% 3250
2026
Q1 		$18K Buy
+23,641
New +$27.5K ﹤0.01% 3343

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Vanguard Global Advisers's CGTX Position: Q2 2026 in Review

Vanguard Global Advisers held its Cognition Therapeutics (CGTX) position steady in Q2 2026 at 23,641 shares worth $27.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3250.

Vanguard Global Advisers first reported a position in CGTX in Q1 2026 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Vanguard Global Advisers held 23,641 shares of Cognition Therapeutics worth $27.2K as of Q2 2026.
  • Vanguard Global Advisers left its Cognition Therapeutics share count unchanged in Q2 2026.
  • Cognition Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3250 holding.
  • Vanguard Global Advisers first reported a position in Cognition Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.